Glaucomatous optic neuropathy is the most commonly acquired optic neuropathy encountered in clinical practice. It is the second leading cause of blindness globally, after cataracts, but it presents a greater public health challenge than cataracts, because the blindness it causes is irreversible. It has pathogenesis still largely unknown and no established cure. Alterations in serum antibody profiles, upregulation, and downregulation have been described, but it still remains elusive if the autoantibodies seen in glaucoma are an epiphenomenon or causative. Hypertension, diabetes, and hearing disorders also are associated. This review is a glaucoma update with focus about the recent advances in the last 15 years.
Glaucoma: recent advances in the involvement of autoimmunity / Rizzo, MARIA IDA; Greco, Antonio; DE VIRGILIO, Armando; Gallo, Andrea; Taverniti, Luciano; Fusconi, Massimo; Conte, Michela; Pagliuca, Giulio; Turchetta, Rosaria; DE VINCENTIIS, Marco. - In: IMMUNOLOGIC RESEARCH. - ISSN 0257-277X. - 65:1(2017), pp. 207-217. [10.1007/s12026-016-8837-3]
Glaucoma: recent advances in the involvement of autoimmunity
RIZZO, MARIA IDAPrimo
;GRECO, AntonioSecondo
;DE VIRGILIO, ARMANDO
;GALLO, Andrea;TAVERNITI, Luciano;FUSCONI, Massimo;CONTE, MICHELA;PAGLIUCA, GIULIO;TURCHETTA, RosariaPenultimo
;DE VINCENTIIS, MarcoUltimo
2017
Abstract
Glaucomatous optic neuropathy is the most commonly acquired optic neuropathy encountered in clinical practice. It is the second leading cause of blindness globally, after cataracts, but it presents a greater public health challenge than cataracts, because the blindness it causes is irreversible. It has pathogenesis still largely unknown and no established cure. Alterations in serum antibody profiles, upregulation, and downregulation have been described, but it still remains elusive if the autoantibodies seen in glaucoma are an epiphenomenon or causative. Hypertension, diabetes, and hearing disorders also are associated. This review is a glaucoma update with focus about the recent advances in the last 15 years.File | Dimensione | Formato | |
---|---|---|---|
Rizzo_Glaucoma recent advances_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
643.16 kB
Formato
Adobe PDF
|
643.16 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.